Background: Information regarding longer-term outcomes in JIA largely pre-date the introduction of biologic therapies and have been cross-sectional. Objectives: The aim of this study was to assess outcomes over the first 5 years of disease in children diagnosed with oligoarticular and polyarticular JIA since 2001. Methods: Children with oligoarthritis, rheumatoid-factor (RF) negative or positive polyarthritis were selected if recruited to the Childhood Arthritis Prospective Study (CAPS), a UK multicentre inception cohort, between October 2001 and January 2011. The following outcomes were assessed annually to five years and included in this analysis: functional ability (Childhood Health Assessment Questionnaire (CHAQ)), the absence of limited joints, overall psychosocial health (psychosocial scale on the Child Health Questionnaire (CHQ)) and the proportion of children with CHQ psychosocial scores two standard deviations below the population mean (CHQ psychosocial<30). Outcomes were assessed descriptively over time and differences between subtypes were assessed by applying multilevel (patient-level) zero-inflated negative binomial (CHAQ), logistic (absence of limited joints, percent CHQ psychosocial<30) and linear (CHQ psychosocial) regression analyses, adjusting for gender, age at presentation and hospital. Results: Of 832 children, 70% were female, 68% had oligoarticular, 28% RFnegative and 5% RF-positive polyarticular JIA. Eighty four percent had ever been treated with NSAIDs, 74% corticosteroids, 55% with DMARDs and 21% with biologics within follow-up. Baseline CHAQ was good to moderate (median 0.8, IQR 0.1 to 1.4) and only 21% of children had no limited joints reported at this time. CHQ psychosocial scores (median 50, IQR 39 to 55) were moderate, with 11% children scoring at least two standard deviations under the population mean. Overall improvements were evident in all outcomes over the first year then remained stable with no further improvements at the cohort level evident to five years. Patients with RF-negative polyarthritis experienced significantly poorer outcomes across all variables than those with oligoarthritis. Those with RF-positive polyarthritis recorded similar CHAQ scores to patients with RF-negative polyarthritis but had the lowest odds of no limited joints (OR: 0.4, 95% CI 0.3 to 0.7) and the poorest CHQ psychosocial scores (4.8 points worse and 4.7 times the odds of scores <2 standard deviations of population mean), compared with those with oligoarthritis. Conclusions: On average, the largest improvement in functional ability, limited joints and psychosocial health occur in the first year following diagnosis, perhaps confirming the importance of early treat-to-target strategies. Patients with polyarticular JIA subtype have poorer parent and physician-reported outcomes than those with oligoarthritis.
THU0489 ADIPOSITY AND INFLAMMATORY ACTIVITY IN JUVENILE IDIOPATHIC ARTHRITIS COULD THEY BE RELATED?
G. Diaz Background: Adults with rheumatoid arthritis have been shown to have a reduction in lean mass and increased adiposity, despite presenting normal Body Mass Index (BMI). Several studies have shown increased adiposity induces a proinflammatory state which lead to a worse response to treatment. There are few publications about this subject in juvenile idiopathic arthritis (JIA) Objectives: Describing body composition and anthropometric parameters in JIA patients, and evaluating relationship between adiposity and inflammatory in these children. Methods: Observational cross-sectional study, in JIA patients from 4 to 15 years, monitored by a Pediatric Rheumatology Unit. Monoarticular forms were excluded. Anthropometric, clinical and treatment data were recorded. DXA (measuring bone and fat mass) were obtained. Fat Mass Index (FMI) was defined as fat mass (kg)/height (m 2 ) and fat-free mass index (FFMI) as lean mass (kg)/height (m 2 ). JADAS27 index was used to evaluate inflammatoty activity.
Results:
We analyzed 80 patients, whose characteristics are shown in table 1. The most frequent JIA subtype was oligoarticular (16.3% extended,47.5% persistent) followed by polyarticular (25.1%). Twenty five percent of patients had uveitis. Fifty percent them had inactive disease with treatment, 26% had activity and 23% were inactive without treatment. Regarding the treatment, 52.5% were on methotrexate and 30% on a biological drug (22.5% antiTNFα, 5% antiIL-1, 2.5% antiIL-6). Disease duration average was 6.6 years (± 3.7SD). JADAS27 index mean score was 2 (±4SD), CRP 4.7mg/l (±9,5SD), ESR 8.7mm (±7,2SD) and CHAQ 0.17 (± 0,38SD). Anthropometric parameters are shown in table 1. Mean JADAS27 index score in patients with normal BMIwas lower (1.7±3.6 SD) than mean JADAS27 index score in overweight and obese patients (3.3±6.0SD), although this difference was not significantly (p=0.255). In multiple linear regression, an increase of 0.3 JADAS27 was observed for each unit of FMI increase (p=0.03). This relationship was maintained in the multivariate analysis (B0.015; p0.01) independently of JIA subtype and received treatment. Background: Glomerulonephritis is an important cause of morbidity and mortality in patients with systemic lupus erythematosus, particularly in children. Presently, renal histology is used for the diagnosis of lupus nephritis (LN), but it only offers a description of a confined area of the kidney and is seldom repeated for monitoring due to its invasiveness. Urinary biomarkers that reflect LN activity and have prognostic value are much needed to guide the judicious use of immunosuppressive drugs in these patients. We focused on three potential LN biomarkers: HER2, TWEAK and VCAM1. HER2 (Human Epidermal Growth Factor Receptor 2) controls cell proliferation by regulating the intracellular levels of miR-26a and miR-30b, which inhibit the expression of cell-cycle related genes. HER2 was recently shown to be dramatically overexpressed in the kidneys of LN patients and in NZM2410 mice. 
